Clinical Trials
10 trialsNCT04233567 2026-02-24
Infigratinib for the Treatment of Advanced or Metastatic Solid Tumors in Patients With FGFR Gene Mutations
Ohio State University Comprehensive Cancer Center
Phase 2 Completed
NCT06206278 2024-08-14
Evaluation of Infigratinib in Patients With Locally Advanced or Metastatic Gastric Cancer or GEJ Adenocarcinoma
LianBio LLC
Phase 2 Terminated
NCT02159066 2024-03-05
LOGIC-2
Pfizer
Phase 2 Completed
NCT05514912 2023-12-26
Preoperative Nab-paclitaxel, Cisplatin, and Gemcitabine Chemotherapy With or Without Infigratinib Targeted Therapy for the Treatment of Resectable Intrahepatic Cholangiocarcinoma, The OPTIC Trial
Emory University
Phase 2 Withdrawn
NCT02150967 2023-07-03
A Phase II, Single Arm Study of BGJ398 in Patients With Advanced Cholangiocarcinoma
QED Therapeutics, a BridgeBio company
Phase 2 Terminated
NCT05019794 2022-06-27
FGFR
LianBio LLC
Phase 2 Unknown
NCT03510455 2021-04-08
BGJ398 for the Treatment of Tumor-Induced Osteomalacia
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT01975701 2019-12-04
A Phase 2 Study of BGJ398 in Patients With Recurrent GBM
Novartis
Phase 2 Completed
NCT02160041 2019-06-18
CBGJ398XUS04
Novartis
Phase 2 Terminated
NCT02706691 2019-04-16
BGJ398 in Treating Patients With FGFR Positive Recurrent Head and Neck Cancer
University of Chicago
Phase 2 Terminated